ReviewWiener medizinische Wochenschrift (1946)2010
Neuropathic Gaucher disease.
Review in Wiener medizinische Wochenschrift (1946), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Phenotypic Spectrum of Type 2-3 Gaucher Disease: A Case Study in the Balkan Genotype.The American journal of case reports · 2026Article
- Synaptic vesicle endocytosis deficits underlie cognitive dysfunction in mouse models of GBA-linked Parkinson's disease and dementia with Lewy bodies.Nature communications · 2025Article
- Gaucher Disease: An Unusual Cause of Knee Pain.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2022Article
- A Brief Review of In Vitro Models for Injury and Regeneration in the Peripheral Nervous System.International journal of molecular sciences · 2022Review
- Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease.Biomolecules · 2020Article
- Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher disease.Molecular genetics and metabolism reports · 2020Article
- Polyneuropathy in Gaucher disease type 1 and 3 - a descriptive case series.Scientific reports · 2019Article
- Twenty- five years of biochemical diagnosis of Gaucher disease: the Egyptian experience.Heliyon · 2019Article
- Gaucher Disease: New Expanded Classification Emphasizing Neurological Features.Iranian journal of child neurology · 2019Review
- Fever, pulmonary interstitial fibrosis, and hepatomegaly in a 15-year-old boy with Gaucher disease: a case report.Journal of medical case reports · 2018Article
- Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.Blood cells, molecules & diseases · 2018Article
- Proton MR Spectroscopy of the brain in children with neuronopathic Gaucher's disease.European radiology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gaucher disease (GD) has been conventionally demarcated into clinical variants, based on the presence or absence of primary central nervous system (CNS) involvement. In cases with primary CNS involvement (types 2 and 3 GD), distinctions have been made on the basis of severity and rate of disease progression. Although the type 1 GD variant had been designated non-neuropathic, recent studies have revealed that affected individuals have an increased risk of developing peripheral neuropathy and parkinsonian features. There is a need for greater understanding of the neurologic features of GD, as these aspects of the phenotype are the most recalcitrant to current therapy. Significant advances in therapy have been achieved, primarily through enzyme replacement, for the systemic, extra-neurologic features among patients with types 1 and 3 GD. Improved understanding of the pathophysiologic basis of neurologic involvement may enable development of therapies that may have a positive influence on neurologic outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.